Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
l�ll
Vildagliptin: a new oral treatment for type 2 diabetes mellitus Mathieu C; Degrande EVasc Health Risk Manag 2008[]; 4 (6): 1349-60Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose. An extensive clinical program involving approximately 22,000 patients and 7000 patient-years of exposure to vildagliptin has shown that the agent is well tolerated and efficacious in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). Monotherapy trials have shown that significant HbA1c lowering is accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make vildagliptin a favorable partner for combination therapy. Studies of vildagliptin as an add-on to metformin have shown significant improvements in glycemic control (comparable to that of thiazolidinedione add-on), with the combination being well tolerated and associated with low risks for hypoglycemia and adverse effects on weight or lipid levels. Good tolerability and clinically relevant improvements in glycemic control have also been observed with vildagliptin as an add-on treatment to sulfonylurea, thiazolidinedione, or insulin treatment or in initial combination treatment with pioglitazone. Improved beta-cell function and glycemic control have been shown with vildagliptin in subjects with impaired glucose tolerance and in T2DM patients with mild hyperglycemia, with some evidence in the latter suggesting the potential for modifying disease course.|Adamantane/administration & dosage/adverse effects/*analogs & derivatives[MESH]|Administration, Oral[MESH]|Blood Glucose/drug effects[MESH]|Clinical Trials as Topic[MESH]|Diabetes Mellitus, Type 2/blood/*drug therapy[MESH]|Drug Therapy, Combination[MESH]|Glycated Hemoglobin/metabolism[MESH]|Humans[MESH]|Hypoglycemic Agents/*administration & dosage/adverse effects[MESH]|Insulin-Secreting Cells/drug effects/metabolism[MESH]|Nitriles/*administration & dosage/adverse effects[MESH]|Pyrrolidines/*administration & dosage/adverse effects[MESH]|Severity of Illness Index[MESH]|Time Factors[MESH]|Treatment Outcome[MESH]|Vildagliptin[MESH] |